Replies to post #195968 on Avid Bioservices Inc (CDMO)

[revenue_monster]

It's PPHM. You never have certainty.

[mojojojo]

It looks like we're getting results but they aren't going to be the survival numbers. This is taken from the companies 9/9/2014 PR.

A Phase I/II IST evaluating bavituximab in combination with sorafenib in up to 48 patients with advanced hepatocellular carcinoma (liver cancer) has completed enrollment of the Phase II portion and data from this trial are expected to be presented at an upcoming conference.
"The Phase II portion of this trial has completed enrollment with a number of patients currently on treatment, the longest of whom has been on treatment for 18 months," said Adam Yopp, M.D. Assistant Professor of Surgery at the University of Texas Southwestern Medical Center's Simmons Cancer Center. "While the results from this trial are preliminary, I believe they are promising. I am excited about this potential combination given the new understandings about bavituximab's mechanism and I look forward to sharing the full set of data from this Phase II trial at a future scientific conference."

...Data from the company's immuno-oncology program, as well as clinical translational data aimed at assessing and measuring changes in immune response pre- and post-treatment from the liver cancer IST will be the subject of presentations at the 29th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC) to be held November 6-9, 2014.